Company / Free Cash Flow per Share
UroGen Pharma Ltd. Free Cash Flow per Share History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Free Cash Flow per Share
-$3.85
FY2025
5-year range
-$3.86 / -$2.36
FY2021-FY2025
Trend
-63.5%
vs FY2024
Sector context
#168 of 192
Health Care
What the data says
UroGen Pharma Ltd.'s free cash flow per share of $-3.85 is lower than 87% of companies in the Health Care sector (FY2025). Free Cash Flow per Share has fluctuated over the past 10 years, ranging from $-3.86 in FY2021 to $1.52 in FY2016.
Based on SEC 10-K filings.
-3.85 in FY2025.
Remained stable around $-3.85 over the past 2 years.
Health Care sector context is included.
Free Cash Flow per Share over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 13% in Health CareTop 87% of 192This company -$3.85 Sector average -$19.84
▼
+80.6% above sector average
Key checks
Key Insights
- In FY2025, free cash flow per share decreased 63.5% year-over-year.
- Ranks #168 out of 192 companies in the Health Care sector.
- Peak free cash flow per share was recorded in FY2016.
- Lowest free cash flow per share in the period was in FY2021.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -5.09 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Free Cash Flow per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$3.85 | -63.5% |
| FY2024 | -$2.36 | +37.9% |
| FY2023 | -$3.80 | +0.4% |
| FY2022 | -$3.81 | +1.3% |
| FY2021 | -$3.86 | -13.9% |
| FY2020 | -$3.39 | -459.2% |
| FY2019 | -$0.61 | +78.0% |
| FY2018 | -$2.76 | -172.1% |
| FY2017 | -$1.01 | -166.8% |
| FY2016 | $1.52 | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026